Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6‐week, double‐blind, placebo‐controlled study

Abstract

Quetiapine did not significantly improve psychosis scores. It did not cause cognitive and motor deterioration. These results might possibly be due to small sample size.

Baseline imbalances and clinical outcomes of atypical antipsychotics in dementia: A meta‐epidemiological study of randomized trials

“…The first author of two trials provided additional data (De Deyn et al, , ). For another trial, we calculated the missing baseline information with the provided IPD (Paleacu et al, ).…”

“…For all extracted information, the published article of a trial was our primary source. Authors provided additional information at our request (De Deyn et al, ; De Deyn, Jeste, Swanink, Kostic, & Breder, ; Kurlan, Cummings, Raman, & Thal, ; Paleacu, Barak, Mirecky, & Mazeh, ; Schneider et al, ) and meta‐analyses published by industry were our secondary source. Other articles and meta‐analyses were our tertiary source of information (Ballard, Waite, & Birks, ; Carson, McDonagh, & Peterson, ; Cheung & Stapelberg, ; Lee et al, ; Lonergan, Luxenberg, Colford, & Birks, ; Maher et al, ; Schneider, Dagerman, & Insel, ; Seitz et al, ).…”

Randomized double‐blind placebo‐controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease

“…Previous studies showed that atypical antipsychotic drugs, which are commonly used in dementia, did not show significant differences for the treatment of BPSD between placebo and active groups in double-blind clinical trials. 22,23 Standardization of non-pharmacotherapy at all sites would be of importance in future trials.…”

Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials

“…Data from small trials did not demonstrated any advantage of QUE over PLA in improving agitation or psychotic symptoms in patients with dementia and parkinsonism (Kurlan et al 2007) or with specific diagnosis of Alzheimer's disease (Paleacu et al 2008). Where the superiority was demonstrated, it merely emerged from a post hoc analysis of secondary outcome measures (Zhong et al 2007).…”

“…Among the three trials available on QUE, overall including less than 300 patients (Kurlan et al 2007;Zhong et al 2007;Paleacu et al 2008), two demonstrated that the efficacy of the drug was similar to that shown by PLA (Kurlan et al 2007;Paleacu et al 2008) Three of the four available trials (Katz et al 1999;Brodaty et al 2003;Frank et al 2004) that provided original data on the use of RIS in treating dementia-related psychotic and behavioural symptoms (overall involving 664 patients), although suffering from the same limitations shown by studies on the other SGAs, were concordant in suggesting that RIS, used at a wide range of daily dose (0.5-7.0 mg), was more effective than PLA. However, the trial by Mintzer et al (2006), conducted on a relatively large sample and which specifically selected patients with AD suffering from delusions or hallucinations, showed no significant clinical effects of two fixed daily doses (1.0 or 1.5 mg) of RIS.…”